Loading...
XNAS
KIDS
Market cap549mUSD
Jun 10, Last price  
22.17USD
1D
2.92%
1Q
-13.19%
IPO
18.24%
Name

OrthoPediatrics Corp

Chart & Performance

D1W1MN
XNAS:KIDS chart
P/E
—
P/S
2.68
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.55%
Rev. gr., 5y
23.06%
Revenues
205m
+37.65%
23,684,00031,004,00037,298,00045,620,00057,559,00072,552,00071,078,00098,049,000122,289,000148,732,000204,727,000
Net income
-38m
L+80.33%
-9,549,000-7,891,000-6,572,000-8,932,000-12,025,000-17,199,000-32,944,000-16,260,0001,258,000-20,974,000-37,822,000
CFO
-27m
L+0.01%
-9,922,000-892,000-1,119,000-7,217,000-15,583,000-17,769,000-18,530,000-13,063,000-21,766,000-27,046,000-27,048,000
Earnings
Aug 04, 2025

Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
URL
https://www.orthopediatrics.com/
IPO date
Oct 12, 2017
Employees
203
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
204,727
37.65%
148,732
21.62%
122,289
24.72%
Cost of revenue
234,248
174,498
144,079
Unusual Expense (Income)
NOPBT
(29,521)
(25,766)
(21,790)
NOPBT Margin
Operating Taxes
(4,107)
(338)
(4,947)
Tax Rate
NOPAT
(25,414)
(25,428)
(16,843)
Net income
(37,822)
80.33%
(20,974)
-1,767.25%
1,258
-107.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
139,282
BB yield
-16.74%
Debt
Debt current
160
152
144
Long-term debt
23,957
11,020
1,255
Deferred revenue
Other long-term liabilities
23,381
10,146
11,491
Net debt
(44,716)
(69,134)
(116,891)
Cash flow
Cash from operating activities
(27,048)
(27,046)
(21,766)
CAPEX
(14,263)
(16,878)
(10,031)
Cash from investing activities
(13,162)
41,677
(113,371)
Cash from financing activities
53,135
7,301
135,974
FCF
(64,824)
(60,635)
(48,318)
Balance
Cash
68,833
80,306
118,290
Long term investments
Excess cash
58,597
72,869
112,176
Stockholders' equity
(246,331)
(203,262)
(182,162)
Invested Capital
682,357
600,493
573,208
ROIC
ROCE
EV
Common stock shares outstanding
23,078
22,675
20,948
Price
23.18
-28.70%
32.51
-18.17%
39.73
-33.63%
Market cap
534,941
-27.43%
737,180
-11.42%
832,253
-27.84%
EV
490,225
668,046
715,362
EBITDA
(10,441)
(8,381)
(8,691)
EV/EBITDA
Interest
2,621
2,424
Interest/NOPBT